← Back to Search

Stimulant

Caffeine for Caffeine

Phase < 1
Waitlist Available
Led By Andriy Yabluchanskiy, MD, PhD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline measurements 1 hour after treatment
Awards & highlights

Study Summary

This study is evaluating whether caffeine may have positive impacts for individuals with major depressive disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline measurements 1 hour after treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline measurements 1 hour after treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cerebrovascular reactivity using functional near infrared spectroscopy (fNIRS)
Cerebrovascular reactivity using transcranial Doppler
Structure of blood vessel of retina
+2 more

Side effects data

From 2016 Phase 3 trial • 133 Patients • NCT01462318
44%
Multiple sclerosis relapse
25%
Upper respiratory tract infection
23%
Urinary tract infection
16%
Headache
14%
Nasopharyngitis
11%
Pharyngitis
11%
Back pain
10%
Influenza like illness
9%
Fatigue
9%
Pyrexia
8%
Muscular weakness
8%
Sinusitis
8%
Arthralgia
8%
Anxiety
7%
Hypoaesthesia
7%
Depression
7%
Pain in extremity
7%
Insomnia
7%
Diarrhoea
7%
Alanine aminotransferase increased
6%
Influenza
6%
Lymphadenopathy
5%
Oral herpes
5%
Muscle spasms
5%
Spinal pain
5%
Migraine
5%
Muscle spasticity
5%
Hypothyroidism
2%
Pneumonia
2%
Postmenopausal haemorrhage
1%
Sarcoidosis
1%
Autoimmune hepatitis
1%
Neutropenia
1%
Streptococcal urinary tract infection
1%
Toxicity to various agents
1%
Obesity
1%
Lumbar spinal stenosis
1%
Furuncle
1%
Hepatitis E
1%
Hepatic enzyme increased
1%
Infection
1%
Haemolytic anaemia
1%
Suicide attempt
1%
Abortion missed
1%
Hydronephrosis
1%
Endometrial hypertrophy
1%
Endometriosis
1%
Ovarian cyst
1%
Cutaneous sarcoidosis
1%
Erythema nodosum
1%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
DAC HYP 150 mg

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CaffeineExperimental Treatment1 Intervention
Participants randomized to caffeine group will receive 100mg caffeine capsule
Group II: ControlPlacebo Group1 Intervention
Participants randomized to placebo group will receive placebo capsule
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Caffeine
2014
Completed Phase 3
~2980

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
455 Previous Clinical Trials
95,913 Total Patients Enrolled
Andriy Yabluchanskiy, MD, PhDPrincipal InvestigatorUniversity of Oklahoma
3 Previous Clinical Trials
116 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Oklahoma
How old are they?
18 - 65
What site did they apply to?
Translational GeroScience Laboratory
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Caffeine and Cerebrovascular Reactivity
2021. "Caffeine and Cerebrovascular Reactivity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04730193.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top